Lower urinary dysfunction as a long-term effect of childhood vincristine treatment, with potential influences by sex and dose by Nao Iguchi, Ali Teimouri, Duncan T. Wilcox, Anna P. Malykhina, Nicholas G. Cost

“…Abstract Vincristine (VCR) is one of the most widely used chemotherapy agents in treating pediatric cancer. Nonetheless, it is known to cause dose-dependent neurotoxicity which can impact virtually every organ system. …”
Get full text

Effect of “Time To Surgery” on the Endometrial Cancer Prognosis by Engin Celik, Harika Yumru Celiksoy, Hamdullah Sozen, Hale Goksever Celik, Semen Onder, Mehmet Yavuz Salihoglu, Samet Topuz

“…STUDY DESIGN: Patients who were diagnosed with epithelial type endometrial cancer and did not receive preoperative chemotherapy, radiotherapy, or hormonal therapy were included in the study. …”
Get full text

Aetiology of haemorrhagic cystitis: BK Polyomavirus and Adenovirus detection by Yoliswa Z. Chili, Menzi B. Nkosi, Nicky-Louise Byrne, Moepeng J. Maseko, Stephen N.J. Korsman, Gert U. Van Zyl

“…This case report details haemorrhagic cystitis in a 49-year-old female with chronic lymphocytic leukaemia (CLL), recurrent haematuria and detected BK polyomavirus (BKPyV) and adenovirus (HAdV) in urine. During chemotherapy cycles, quantitative polymerase chain reaction (PCR) assays found high HAdV load, similar to a HAdV-B2 genotype 78, a rare genotype that is closely related to HAdV-11. …”
Get full text

Intracranial ewings sarccoma mimicking middle 1/3rd parasagittal meningioma by Sharad Pandey, Pankaj Kumar, Purnima Paliwal, Achal Saxena, Sumit Deshpande, N. Monica

“…Wide local excision is the treatment of choice. Chemotherapy has been shown to improve long-term survival rates and lower recurrence rates. …”
Get full text

Primary liver lymphoma: review of the literature and clinical case presentation by A. K. Smolyaninova, A. V. Gubkin, Ye. Ye. Zvonkov, Yu. A. Kucheryavy

“…Despite of rapid disease progression with development of severe liver failure, that resulted in poor prognosis, patient demonstrated significant response to high-dose chemotherapy and achieved long-term remission. Summary. …”
Get full text

Therapeutic strategies for fungating and ulcerating breast cancers: A systematic review and narrative synthesis by Valentina Zagardo, Mandara Harikar, Gianluca Ferini

“…Cohort analysis revealed a significant positive correlation between metastasis rate and radiotherapy use (Spearman's rho = 0.828, p = 0.042) and between chemotherapy and hormonal therapy use (rho = 0.69, p = 0.04). …”
Get full text

Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States by Robert L. Coleman, Jamie Garside, Jean Hurteau, Joehl Nguyen, Monica Kobayashi

“…**Discussion:** The use of platinum-based chemotherapy for first-line treatment of advanced or recurrent EC predominates in the real-world setting, despite the poor long-term survival outcomes associated with most of these regimens. …”
Get full text

Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma by Erin E. Crotty, Aimee A. Sato, Aimee A. Sato, Mohamed S. Abdelbaki

“…Recent biologic insights and therapeutic targeting of MAPK-alterations have dramatically shifted the treatment approach in pLGG. While chemotherapy remains front-line therapy for unresectable pLGG in most scenarios (with the notable exception of BRAFV600E-altered tumors), many patients recur following cytotoxic agents and require further treatment. …”
Get full text

MicroRNA-155 modulates methotrexate-induced spatial memory impairment by disruption of the blood-brain barrier integrity by Yu-Chieh Chen, Li-Tung Huang, Hong-Ren Yu, Jiunn-Ming Sheen

“…Aim: Methotrexate (MTX) is a commonly used chemotherapy drug, yet its late neurotoxic side effects are gaining attention. …”
Get full text

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma by Suzy Van Sanden, Ayman Youssef, Simona Baculea, Keith Stubbs, Spyros Triantos, Zijiao Yuan, Caitlin Daly

“…**Methods:** An anchored MAIC was conducted according to the National Institute for Health and Care Excellence Decision Support Unit guidance, with physician’s choice of chemotherapy (docetaxel/paclitaxel and vinflunine) as the common comparator. …”
Get full text

PIVKA-II as a surrogate biomarker for therapeutic response in Non-AFP-secreting hepatocellular carcinoma by San-Chi Chen, Hsiang-Ling Ho, Chien-An Liu, Yi‑Ping Hung, Nai-Jung Chiang, Ming‑Huang Chen, Yee Chao, Muh-Hwa Yang

“…This association held for targeted therapies, immune checkpoint inhibitors, and chemotherapy. Progression-free survival (PFS) for the regression, stable, and progression groups was non-reached, 6.7, and 3.2 months (p = 0.0002), and overall survival (OS) was non-reached, non-reached, and 18.5 months (p = 0.02). …”
Get full text

Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report by Linn Z, Gu Z, Wang L, Cai S

“…Following surgery and chemotherapy, the patient commenced maintenance therapy with Olaparib. …”
Get full text

A Woman with a Long History of Smoking and a Debilitating Dry Cough by N. D. Potskhverashvili, N. I. Kokina, E. L. Bueverova, O. Yu. Zolnikova, A. S. Cherenda, V. A. Morozova, M. V. Feldsherov, A. P. Kiryukhin, P. V. Pavlov

“…Surgical treatment was performed at the Sechenov University surgical hospital: right-sided hemicolectomy with D2 lymph dissection (removal of epicolic, paracolic, mesocolic lymph nodes); adjuvant chemotherapy was prescribed. The patient is under the supervision of an oncologist and a coloproctologist.Conclusion. …”
Get full text

PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials by Samuel Pratama, Lowilius Wiyono, Martien Silviandy Setiawan, Brigitta Cindy Lauren

“…Conclusion: The addition of PARPi in the chemotherapy regimen for patients with SCLC results in increased PFS and ORR, with no difference in OS and an increased risk of TEAEs. …”
Get full text

Costs and Resource Use Among Patients with Cervical Cancer, Cervical Intraepithelial Neoplasia, and Genital Warts in Algeria by Ali-Chakib Bennacef, Aomar Ammar Khodja, Fadl Allah Abou-Bekr, Tidiane Ndao, Ryan Holl, Goran Benčina

“…Treatments used regularly or always for cervical cancer included chemotherapy (80%), hysterectomy (70%), and radiation (70%). …”
Get full text

Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based... by Scott Goulden, Qin Shen, Robert L. Coleman, Cara Mathews, Matthias Hunger, Ankit Pahwa, Rene Schade

“…**Background:** Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite instability–high advanced or recurrent EC. …”
Get full text

The effect of ileostomy closure timing on low anterior resection syndrome in patient who underwent low anterior resection for rectal cancer by Hemn Hussain Kaka Ali, Qalandar Hussein Abdulkarim, Karzan Seerwan, Barham M. M .Salih, Omar H Ghalib Hawramy, Dara Ahmed Mohammed, Syamand Orhaman Ahmed

“…Ileostomy had been done to protect low lying Colo-rectal anastomosis, closure of ileostomy had been delayed in some patients due to patient own will, surgical complications (anastomotic leak) or coarse of chemotherapy. This study aimed to find the effect of temporary ileostomy on post-operative bowel defunction which is called Low anterior resection syndrome (LARS), and include; urgency, difficulty in emptying of bowel, and incontinence for feces and flatus.  …”
Get full text

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry by Frederick L Locke, Grant Schofield, Marcelo Pasquini, Matthew J Frigault, Cameron J Turtle, Stephen Lim, Brian Hill, Samantha Jaglowski, Caron A Jacobson, Gunjan Shah, Daniel J Landsburg, Michael Heim, Stephen Ronan Foley, Ron Ram, Peter A Riedell, Leslie L Popplewell, Ranjan Tiwari, Marta Majdan, Aisha Masood

“…Patients with DLBCL (vs HGBCL), complete response before infusion, prior autologous or allogeneic haematopoietic stem cell transplant and lactate dehydrogenase (LDH) within normal limits experienced more favourable efficacy outcomes, and those with Eastern Cooperative Oncology Group performance status of ≥2, ≥3 prior lines of therapy, elevated LDH and fludarabine-based lymphodepleting chemotherapy experienced less favourable safety outcomes.Conclusions This real-world study of tisagenlecleucel for patients with R/R DLBCL/HGBCL shows consistent efficacy and better safety outcomes than the pivotal trial. …”
Get full text

Evaluation of treatment strategies for patients with stage IIIA non-small cell lung cancer in the immunotherapy era by Amy Alabaster, Jeffrey B. Velotta, Haley I. Tupper, Mark S. Walker, Yanina Natanzon

“…Growing evidence indicates surgery with adjuvant or neoadjuvant chemotherapy (SC) may be superior to non-surgical treatments. …”
Get full text

Stent as a bridge to surgery for malignant colonic obstruction: a retrospective study on survival and outcomes by Thanawin Wong, Tanawat Pattarapuntakul, Nisa Netinatsunton, Jaksin Sottisuporn, Thanapon Yaowmaneerat, Wongsakorn Chaochankit, Siriboon Attasaranya, Pimsiri Sripongpun, Naichaya Chamroonkul, Viraksakdi Chongsuvivatwong

“…Baseline characteristics were similar except for ASA classification and chemotherapy rates. The median OS was 56.1 months, with no significant differences in OS (51.4 vs. 61.0 months, p = 0.67) or 5-year DFS (53.8% vs. 59.9%, p = 0.32) between the two groups. …”
Get full text